Relevant Articles

Breast Cancer

This 2019 review paper provides a detailed overview of the molecular features of breast cancer, treatment strategies according to molecular subtype, and future therapuetic directions. 

Harbeck, N.; Penault-Llorca, F.; Cortes, J.; Gnant, M.; Houssami, N.; Poortmans, P.; Ruddy, K.; Tsang, J.; Cardoso, F. Breast Cancer. Nature Reviews Disease Primers 2019, 5. https://doi.org/10.1038/s41572-019-0111-2. 

Targeting HER2+ Breast Cancer

This 2023 review paper discusses the current treatments specifically for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy, and new therapuetic approaches. 

‌Swain, S. M.; Shastry, M.; Hamilton, E. Targeting HER2-Positive Breast Cancer: Advances and Future Directions. Nature Reviews Drug Discovery 2023, 22 (2), 1–26. https://doi.org/10.1038/s41573-022-00579-0.

Past Anti-ERBB2 Therapeutics

To understand the current epigenetic approach being developed to treat HER2-positive breast cancer, we must also understand the evolution of anti-ERBB2 therapeutics overtime. The papers linked below document different, novel anti-ERBB2 therapeutics that have been developed within the past 25 years, primarily in the Benz Lab at the Buck Institute for Research on Aging.

ERBB2 Promoter Inhibitors:

• 1994: Triplex-Forming Oligos 

• 2000: Pyrrole-Imidazole Polyamides

Histone Deacetylase Inhibitors (HDACS):

• 2002: Trichostatin A and Sodium Butyrate HDAC Inhibitors

• 2005: Targeted and Non-Targeted Liposomal HDAC Inhibitors

• 2008: Pan-HDAC and HDAC-6 Selective Inhibitors

MicroRNAs (miRNAs):

• 2007: miR-125a and miR-125b miRNAs